• GST-Mediated Lambda-Cyhalothrin Resistance in M. usitatus

  2026-08-08

  Dong and colleagues show that glutathione S-transferase, particularly MuGSTs1, strengthens the antioxidant defense of Megalurothrips usitatus during lambda-cyhalothrin exposure. Pharmacological GST inhibition with diethyl maleate reduced antioxidant capacity and sharply increased insecticide sensitivity, providing a mechanistic framework for resistance research.

• TQB3720 Activates Ferroptosis Through AR/GPX4

  2026-08-07

  The reference study identifies an AR/SP1/GPX4 regulatory route through which the second-generation androgen receptor antagonist TQB3720 suppresses prostate cancer growth and promotes ferroptosis. Its combination of cellular, organoid, xenograft, redox, lipid-peroxidation, and transcriptional assays provides a useful framework for linking AR signaling disruption with iron-dependent oxidative cell death.

• ER Stress Impairs Intestinal Stem Cells via GRP78/ATF6/CHOP

  2026-08-07

  This study demonstrates that tunicamycin-induced endoplasmic reticulum (ER) stress significantly impairs intestinal stem cell number and differentiation in mice, mediated by activation of the GRP78/ATF6/CHOP signaling pathway and suppression of the p44/42 MAPK pathway. These findings clarify the molecular link between ER stress and intestinal barrier dysfunction, offering a mechanistic foundation for future research on targeted interventions in gastrointestinal disease.

• Leptin (116-130), amide, mouse: Optimizing Metabolic Researc

  2026-08-06

  Leptin (116-130), amide, mouse empowers researchers to dissect energy homeostasis, obesity, and diabetes mechanisms with precision. This article delivers actionable workflows, troubleshooting guidance, and fresh insights for leveraging this soluble leptin fragment in advanced experimental designs.

• Amikacin Sulfate Applications: Intracellular Delivery & Prot

  2026-08-06

  Amikacin Sulfate empowers researchers with robust, dose-optimized workflows for intracellular targeting of non-tuberculous mycobacterial infections. Explore advanced experimental setups, troubleshooting strategies, and the latest insights on maximizing bactericidal efficacy while minimizing toxicity.

• Resiniferatoxin (RTX): Mechanistic Precision in TRPV1 Resear

  2026-08-05

  Resiniferatoxin (RTX) is redefining the landscape of translational pain research through its ultra-potent, selective targeting of TRPV1-positive sensory neurons. This thought-leadership article details the mechanistic rationale, experimental strategies, and clinical frontiers of RTX, providing actionable insights for researchers seeking to leverage RTX’s unique profile for next-generation analgesic development. Integrating evidence from recent academic reviews and advanced protocols, we explore how RTX’s chemical inactivation of TRPV1 and sensory neuron desensitization can be harnessed to model, modulate, and silence pathological pain in preclinical and clinical settings. This piece differentiates itself by synthesizing mechanistic, workflow, and translational perspectives, offering clear strategic guidance for researchers navigating the competitive and evolving field of TRPV1-targeted analgesia.

• Auranofin: Thioredoxin Reductase Inhibitor for Cancer Resear

  2026-08-05

  Auranofin is a potent thioredoxin reductase inhibitor with low-nanomolar activity. It induces apoptosis through caspase activation and enhances radiosensitivity in tumor models. This profile summarizes its mechanism, evidence benchmarks, and key workflow parameters.

• Strategic Leverage of Tunicamycin in ER Stress and Stem Cell

  2026-08-04

  This thought-leadership article explores how Tunicamycin, a benchmark N-glycosylation inhibitor, is transforming our mechanistic and translational understanding of endoplasmic reticulum (ER) stress pathways in both inflammation suppression and hematopoietic stem cell (HSC) mobilization. We synthesize recent evidence on SERCA-mediated ER stress, review protocol best practices, and provide strategic guidance for translational researchers aiming to bridge foundational biology with clinical innovation. By contextualizing APExBIO’s Tunicamycin within these advances—and highlighting where this discussion transcends typical product literature—we illuminate emerging frontiers for experimental design and therapeutic exploration.

• Anisomycin (SKU B6674): Reliable JNK Agonist for Apoptosis R

  2026-08-04

  This article addresses key challenges in apoptosis and cell viability assays, revealing how Anisomycin (SKU B6674) from APExBIO offers reproducible, data-driven solutions. Scenario-driven guidance illustrates best practices for JNK pathway activation, protocol optimization, and reliable product selection, empowering researchers to streamline workflows and enhance result consistency.

• AI-Derived Prognostic Signature Refines HCC Risk Stratificat

  2026-08-03

  This multi-center study introduces a consensus artificial intelligence-driven prognostic signature (CAIPS) for hepatocellular carcinoma, outperforming previous models in predicting patient outcomes and therapeutic responses. CAIPS leverages integrated machine learning and multi-omics profiling, providing a robust biomarker framework for precision oncology applications.

• JHU-083 (BA7770): Reliable Glutaminase Pathway Research

  2026-08-03

  This article guides biomedical researchers through common challenges in glutaminase pathway research, highlighting how JHU-083 (SKU BA7770) delivers reproducibility and data-driven results in viability and neurotoxicity assays. Each scenario unpacks practical solutions for workflow optimization, referencing validated protocols and product data.

• PPARα Activation Inhibits Pyroptosis in Cholestatic Liver In

  2026-08-02

  The reference study demonstrates that pharmacological activation of PPARα significantly reduces lithocholic acid-induced cholestatic liver injury in mice by suppressing both NLRP3- and APAF-1-mediated pyroptosis pathways. These mechanistic insights highlight the potential of selective PPARα agonists for dissecting cell death pathways and inflammation in metabolic disorder research.

• Otilonium Bromide in Precision Neuroscience: Mechanisms and

  2026-08-01

  Explore the advanced mechanisms of Otilonium Bromide as an antimuscarinic agent. This article uniquely analyzes its role in precision neuroscience and assay development, providing new insights for researchers.

• Romidepsin (FK228): Unlocking HDAC2-Spliceosome Axis for Can

  2026-07-31

  Explore how Romidepsin (FK228) advances cancer epigenetics by targeting HDAC2-dependent spliceosome regulation. This article reveals novel mechanistic insights and practical assay guidance for researchers, highlighting unique applications beyond existing workflow-centric content.

• M344 as a Histone Deacetylase Inhibitor in Neuroblastoma The

  2026-07-31

  The reference study demonstrates that M344, a potent histone deacetylase inhibitor, effectively suppresses neuroblastoma tumor growth and modulates HDAC-associated phenotypes. These findings highlight M344’s mechanistic advantages and therapeutic potential over established HDAC inhibitors, supporting its role in translational neuroblastoma research and combinatorial cancer therapy.

15783 records 1/1053 page Next 12345 下5页 Last page